Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb: Lack Of Compromise On Right-To-Try Bill Is 'Interesting Lesson In Politics' For Stakeholders

Executive Summary

In interview with the Pink Sheet, former US FDA commissioner Scott Gottlieb said that opposition to the modified House version of the right-to-try legislation ultimately led to the less favorable Senate bill becoming law. 
Advertisement

Related Content

‘Project Facilitate’: US FDA Plans May Meeting On Expanded Access Call Center
Right To Try Conversation Should Be Redirected Toward Reimbursement Of Unapproved Drugs, Experts Say
Unlicensed Stem Cell Clinics Are 'Surrogate' For Right To Try, US FDA's Marks Says
US FDA Right To Try Policy: For Now, Defer Questions To Sponsors, Bill Text
'Right-To-Try' Has US FDA Support: Scaled-Back House Bill Retains Agency Oversight
Right-To-Try Opponents Brace For Last Chance To Stop Bill
New Right To Try Bill Fails To Persuade
Right-To-Try Legislation Must Change Language To Narrow Spectrum Of Patients, Gottlieb Says
Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

Topics

Advertisement
UsernamePublicRestriction

Register

PS125291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel